Specialty Drug

Employer Perspectives Specialty Drug Step-Therapy Program Evaluation

Posted on by John Santilli

Employer Perspectives Specialty Drug Step-Therapy Program Evaluation American Health and Drug Benefits, September 2016 Vol 9, No 6 – Industry Trends Matthew Harman, PharmD, MPH, Director, Clinical Pharmacy Strategies Employers Health, Columbus, OH F. Randy Vogenberg, PhD, RPh, Strategic Advisor and Co–Project Leader, Midwest Business Group on Health National Employer Biologics & Specialty Drug Initiative […]

Continue reading →
Trends

Insurers-Hospitals Face Cost Structure Change

Posted on by John Santilli
Knowsource.com Announces Transition to Access Market Intelligence
05
Oct

Insurers-Hospitals Face Cost Structure Change Insurance fundamentals (risk) that supersede the ACA are driving changes seen in coverage, and at a more rapid pace each year, resulting from ACA impacts. One of those changes has been a significant increase in the use of alternate sites of care (ASOCs) due to medical policy changes driven by […]

Continue reading →
Pharmaceutical, Uncategorized

Managed care pharmacy survey findings 2016

Posted on by John Santilli

Managed care pharmacy survey findings 2016 Managed Healthcare Executive September 26, 2016 To identify the top managed care pharmacy challenges and what your peers are doing about them, Managed Healthcare Executive, in partnership with Access Market Intelligence and the National Institute of Collaborative Healthcare, conducted its first-ever pharmacy survey during the second quarter of 2016. […]

Continue reading →
Specialty Drug

VA Extending Hepatitis C Therapy

Posted on by John Santilli

VA Extending Hepatitis C Therapy as its drug spend for the disease increases rapidly. The department last year allocated $696 million for new hepatitis C drugs, accounting for 17 percent of the VA’s total pharmacy budget. In fiscal 2016, which began Oct. 1, 2015, the VA expects to spend about $1 billion on hepatitis C […]

Continue reading →
Uncategorized

Telehealth Applications Patient Care

Posted on by John Santilli

Telehealth Applications Patient Care Rita M. Marcoux, RPh, MBA; F. Randy Vogenberg, PhD, RPh, FASHP June 2016, Vol 7, No 5 – Employers’ Perspective – Value-Based Cancer Care The term telehealth is used interchangeably with telemedicine by some organizations. However, telemedicine is typically associated with the delivery of traditional clinical diagnosis and monitoring by using […]

Continue reading →
Oncology

Oncology Biosimilars: Opportunity or Not?

Posted on by John Santilli

Oncology Biosimilars: Opportunity or Not? VBCC – April 2016, Vol 7, No 3 – Employers’ Perspective F. Randy Vogenberg, PhD, RPh, Partner Access Market Intelligence Martha M. Rumore, PharmD, JD, MS, LLM, FAPhA The United States has the largest biologic drugs market and high prices for biologics, such as monoclonal antibodies, therapeutic proteins, immunomodulators, and […]

Continue reading →
Oncology

Big Data in Cancer Care: Limitations of Drug Claims

Posted on by John Santilli

Big Data in Cancer Care: Limitations of Drug Claims VBCC – March 2016, Vol 7, No 2 – Employers’ Perspective Catherine E. Cooke, PharmD, BCPS F. Randy Vogenberg, PhD, RPh Partner, National Institute of Collaborative Healthcare, and Access Market Intelligence; Principal, Institute for Integrated Healthcare Greenville, SC As one part of an ongoing macrotheme regarding big […]

Continue reading →
Trends

Impact of Commercial Insurance in 2017

Posted on by John Santilli
Clinical trial collaborations – an idea whose time has come
20
May

Impact of Commercial Insurance in 2017 – Considerable attention and planning has been focused on the Medicare market, but as we see from the chart below, Medicare represents approximately 13% of the total population.   Employer 49% Medicaid 19% Medicare 13% Uninsured 10% Non-Group 6% Other Public 2% (Source: Kaiser Family Foundation) A recent Mercer […]

Continue reading →